Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.

Eugen Feist Roy M Fleischmann Saeed FatenejadDaria BukhanovaSergey GrishinSofia KuzkinaMichael LuggenEvgeniy NasonovMikhail SamsonovJosef S Smolen

Published in: Annals of the rheumatic diseases (2024)

The long-term safety and tolerability of OKZ in combination with MTX remained stable. The efficacy of OKZ was maintained through week 106. These findings support OKZ as a treatment option for patients with active RA.

Keyphrases

high dose
clinical trial
low dose
systemic lupus erythematosus
disease activity
idiopathic pulmonary fibrosis
gestational age
study protocol
preterm birth